New cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07493135
Summary
This early-phase study is testing a new cell therapy called IMV102 in patients with multiple myeloma that has returned or stopped responding to other treatments. The research will check if the treatment is safe and if it helps control the cancer. About 30 patients who have already tried at least three other treatment approaches will receive one infusion and then be followed for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The second affiliated hospital of Chongqing medical university
NOT_YET_RECRUITINGChongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhengzhou Yihe Hospital
NOT_YET_RECRUITINGZhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.